IMAB - Week In Review: Kumquat Signs $2 Billion U.S.-China Deal With Lilly For Novel Immune Drugs
- San Diego-based Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small-molecule drugs that stimulate tumor-specific immune responses in cancer patients.
- Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Hong Kong IPO.
- MicroPort Cardiac Rhythm Management closed a $150 million Series C financing including $20 million from Hillhouse and $47 million from its parent, MicroPort Scientific.
- I-Mab, a Shanghai biotech, announced it is planning to add a listing on the STAR Board of the Shanghai Exchange.
For further details see:
Week In Review: Kumquat Signs $2 Billion U.S.-China Deal With Lilly For Novel Immune Drugs